CARsgen Therapeutics Holdings (HKSE:02171) Net Income From Continuing Operations : HK$-854.89 Mil (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is CARsgen Therapeutics Holdings Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. CARsgen Therapeutics Holdings's net income from continuing operations for the six months ended in Dec. 2024 was HK$-476.43 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-854.89 Mil.

CARsgen Therapeutics Holdings Net Income From Continuing Operations Historical Data

The historical data trend for CARsgen Therapeutics Holdings's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARsgen Therapeutics Holdings Net Income From Continuing Operations Chart

CARsgen Therapeutics Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

Get a 7-Day Free Trial

-1,261.36

-5,800.03

-994.94

-817.48

-851.77

CARsgen Therapeutics Holdings Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Net Income From Continuing Operations	Get a 7-Day Free Trial						-576.12	-442.40	-375.07	-378.47	-476.43

CARsgen Therapeutics Holdings Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-854.89 Mil.

CARsgen Therapeutics Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARsgen Therapeutics Holdings Ltd (HKSE:02171) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 466 Yindu Road, Building 2, 1st Floor, Xuhui District, Shanghai, CHN

Website

https://www.carsgen.com

CARsgen Therapeutics Holdings Ltd is a clinical-stage biopharmaceutical company discovering, researching, and developing cell therapies in the People's Republic of China and the United States of America.

Executives

Bei Jing Shen Nong Tou Zi Guan Li Gu Fen You Xian Gong Si	2102 Investment manager
Candock Holdings Limited	2501 Other
Yi Jie Sheng Wu Ji Shu Kong Gu You Xian Gong Si	2501 Other
Yi De Kong Gu You Xian Gong Si	2501 Other
Quan Zhou Shi Ding Wo Chuang Feng Tou Zi Zhong Xin You Xian He Huo	2501 Other
Yang Xuehong	2501 Other
Wang Huamao	2401 A concert party to an agreement to buy shares
Li Zonghai	2401 A concert party to an agreement to buy shares
Guo Bingsen	2401 A concert party to an agreement to buy shares
Accure Biotech Limited	2501 Other
Cart Biotech Limited	2501 Other
Chen Haiou	2501 Other
Guo Xiaojing	2501 Other
He Xi Holdings Limited	2501 Other
Redelle Holding Limited	2501 Other

CARsgen Therapeutics Holdings Headlines

No Headlines